The invention relates to the field of molecular biology, virology and medicine and concerns novel biologically active compounds, namely, carbamoyl phosphonate salts of the general formula given in the description. The novel compounds are able to selectively inhibit the production of human immunodeficiency virus (HIV), and can therefore be considered for use in the field of medicine for the treatment of AIDS. They are produced by adding an equimolar quantity of ammonia, a corresponding amino compound or alkali or earth-alkali metal hydroxide to an acid form of the carbamoyl phosphonate. The resultant solutions of the salts are boiled down to small volumes, from which spontaneous crystallization starts, and are left at 4°C until the crystallization is complete. The precipitate is filtered and vacuum dried. The target compound yield is 95-98%. The novel compounds inhibit proliferation of HIV-1 in MT-4 lymphocyte cell cultures and are stable compounds, which facilitates drug creation on their basis.
